No Data
No Data
Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, following
Express News | NYSE Halt Bio-Rad Labs B Add Info Lst $283.450400
Incyte, Moderna Among Most Shorted S&P 500 Healthcare Stocks in June
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
S&P 500 Ends First Half Shy Of All-Time Highs. Here Are The Leaders And Laggards — And 5 Stocks That Could Outperform In Next 6 Months
The stock market is up solidly this year, thanks to expectations of rate cuts by the Federal Reserve amid easing inflationary pressure, strong corporate earnings and optimism over the potential of art
RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating
Bio-Rad Laboratories (BIO) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $300 to $430.